Accenture is collaborating with Roche to improve how diabetes care is managed and delivered through the development of a data-driven core analytics platform for Roche’s digital diabetes ecosystem.
The platform and ecosystem will seamlessly connect patients, their caregivers, and healthcare providers with a suite of new digital health services.
Under the terms of a five-year agreement, Roche’s new digital ecosystem and services will be built on the Accenture Intelligent Patient Platform and offered to diabetes patients across Europe.
The open platform will provide Roche with the ability to gather and analyse data in a secure environment, generate new patient insights to provide more-customised care, and easily collaborate and integrate with its ecosystem partners and devices used to manage diabetes care.
Marcel Gmünder, global head of Roche Diabetes Care said “This collaboration agreement with Accenture is an exciting step forward to offering truly-integrated diabetes management solutions. The open diabetes platform we are creating will enable us to analyse large amounts of data through algorithms and put them into context, respond faster to the needs of people with diabetes, caregivers and healthcare systems and personalise treatment which can lead to improved outcomes.”
“The collaboration builds on the trusted relationship we have had over the years. It will enable us to drive digital health in diabetes forward and offer integrated diabetes management solutions and services to shape the way care is being provided in the future, for improved therapy outcomes and more-sustainable healthcare systems.”
This will enable us to drive digital health in diabetes forward and offer integrated diabetes management solutions and services to shape the way care is being provided in the future, for improved therapy outcomes and more-sustainable healthcare systems
Andrea Brückner, who leads Accenture’s life sciences practice in Europe, added: “Uncontrolled diabetes can lead to serious health problems, but also bring about substantial economic loss to those affected by the disease, through direct medical costs and loss of work and wages.”
“We are collaborating with Roche to help combat this illness and to increase the management of secondary health problems by working to change the standard of care and reshaping the industry by seamlessly connecting patients, caregivers and healthcare providers to share information, data and insights to make better care decisions to deliver more-precise, personalised support.”
